Related Experiment Video
Updated: Jan 18, 2026
10:09
Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
Published on: February 14, 2012
52.1K
No one size fits all approach with apomorphine initiation
Christopher Kobylecki1, Richard J B Ellis2
1Department of Neurology, Manchester Centre for Clinical Neurosciences, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, Salford, UK; Division of Neuroscience, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Parkinsonism & Related Disorders
|June 1, 2025
Summary
Continuous subcutaneous apomorphine infusion (CSAI) for Parkinson's disease (PD) motor fluctuations can be initiated at home. Home initiation is safe, effective, and may offer cost savings compared to inpatient settings.
Area of Science:
- Neurology
- Pharmacology
Background:
- Continuous subcutaneous apomorphine infusion (CSAI) is a key treatment for motor fluctuations in advanced Parkinson's disease (PD).
- Access to CSAI can be limited by perceptions and practicalities of treatment initiation.
- Inpatient initiation is common but may be restricted by hospital bed availability.
Purpose of the Study:
- To review evidence for different CSAI initiation approaches.
- To compare inpatient, outpatient/daycase, and home initiation methods for CSAI.
- To assess the safety, efficacy, and accessibility of various CSAI initiation strategies.
Main Methods:
- Literature review of published studies on CSAI initiation.
- Analysis of data regarding inpatient, outpatient/daycase, and home initiation.
- Comparison of complication rates and clinical outcomes across different initiation settings.
Main Results:
- Home initiation of CSAI is effective and safe, comparable to inpatient settings.
- Inpatient initiation allows faster titration but faces access limitations.
- Home initiation may provide potential cost savings and improve patient access.
Conclusions:
- A flexible approach to CSAI initiation, including home-based, can improve access for Parkinson's disease patients.
- Complication rates are comparable across methods, but patient-specific factors are crucial for selection.
- Optimizing CSAI initiation strategies is vital for managing advanced PD motor fluctuations.
Related Concept Videos
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
233
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
233
01:21Factors Affecting Drug Response: Overview
3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K
01:24Dosage Regimen: Individualization
167
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
167
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
690
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
690
01:21Drug Dosing: Obese Patients
226
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
226
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
224
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
224